BIM
CRSP icon

Bogle Investment Management’s CRISPR Therapeutics CRSP Stock Holding History

Bogle Investment Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-91,414
Closed -$3.88M – 333
2020
Q1 		$3.88M Buy
+91,414
New +$4.72M 0.41% 87

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Bogle Investment Management's CRSP Position: Q2 2020 in Review

Bogle Investment Management sold out of CRISPR Therapeutics (CRSP) in Q2 2020, closing a stake of 91,414 shares — an estimated $3.88M sold.

Bogle Investment Management first reported a position in CRSP in Q1 2020 and held it in 1 quarter. The position peaked at $3.88M in Q1 2020. 276 funds tracked by Wall St. Rank hold CRSP as of Q2 2020.

  • Bogle Investment Management reported no remaining CRISPR Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Bogle Investment Management sold 91,414 CRISPR Therapeutics shares in Q2 2020, an estimated $3.88M.
  • Bogle Investment Management first reported a position in CRISPR Therapeutics in Q1 2020 and held it in 1 quarter.
  • Bogle Investment Management's CRISPR Therapeutics position peaked at $3.88M in Q1 2020.
  • 276 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2020.

Based on Bogle Investment Management's 13F filing for Q2 2020, filed 13 Aug 2020.